Novartis Lifts Guidance Again After Key Drugs Help Results

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts’ expectations, boosted by revenue from its key drugs.

Read more at The Wall Street Journal

Save story

Topics

Related

Novartis Lifts Sales Outlook as it Eyes U.S. Expansion
Business - The Wall Street Journal - Yesterday
NatWest Lifts Guidance Again After Quarterly Profit Beat
Business - The Wall Street Journal - October 25
Standard Chartered lifts income guidance again after beating third-quarter profit forecasts
Business - CNBC - October 30
Danske Bank Lifts Guidance After Net Profit Tops Hopes
Business - The Wall Street Journal - October 31
Commerzbank Lifts Guidance as UniCredit Circles
Business - The Wall Street Journal - November 6
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Business - CNBC - October 30
Super Micro shares plunge 17% after company says no timetable for annual results, issues weak guidance
Business - CNBC - November 5

More from The Wall Street Journal

7-Eleven, the Slurpee and a $47 Billion Takeover Battle
Business - The Wall Street Journal - 8 hours ago
He Bought a Sub Shop as a Teen. Now He's Selling Jersey Mike's for $8 Billion.
Business - The Wall Street Journal - 8 hours ago
Auto & Transport Roundup: Market Talk
Business - The Wall Street Journal - 12 hours ago
Energy & Utilities Roundup: Market Talk
Business - The Wall Street Journal - 12 hours ago
Financial Services Roundup: Market Talk
Business - The Wall Street Journal - 12 hours ago